Authors: Qiurong Wang, Chong Li, Zhixia Li, Zan Zhang, Jiansu Zhang
Published: 2025-04-22
DOI: 10.1158/1538-7445.am2025-2951
Source: Full article
The Lymphotoxin B receptor (LTBR) is primarily expressed on epithelial, stromal, and myeloid cells. LTBR signaling has diverse roles, including regulation of lymphoid organ development, induction of tertiary lymphoid structures (TLS), and promotion of liver regeneration. Recently, the therapeutic strategy of activating LTBR to induce and mature TLS has gained momentum, with LTBR-targeting antibodies now advancing into clinical trials. However, traditional preclinical models generally lack expression of human LTBR, which limits the progress of anti-human LTBR antibody development.